Literature DB >> 8140439

Prenatal corticosteroid therapy to prevent respiratory distress syndrome.

E R Yeomans1.   

Abstract

Recently, an editor observed that the number of clinical trials has multiplied and that several trials of the same treatment may be published serially over a span of 10 years or more. He was not discussing antenatal CS therapy, was he? He added that meta-analysis should decide whether characteristics of patients, their therapies, and outcomes in each trial are comparable. Were they? Neither controlled trials in large numbers nor meta-analysis of these trials have swayed obstetricians toward routine use of antenatal CS as a single intervention. Perhaps the data from studies of combined hormonal therapy or of prenatal-postnatal therapy, or of a combination of both of these approaches will increase the use of antenatal CS. Ironically, maybe a retrospective study will provide the stimulus. Time will tell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8140439

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  3 in total

1.  Glucocorticoid regulation of human pulmonary surfactant protein-B mRNA stability involves the 3'-untranslated region.

Authors:  Helen W Huang; Weizhen Bi; Gaye N Jenkins; Joseph L Alcorn
Journal:  Am J Respir Cell Mol Biol       Date:  2007-11-15       Impact factor: 6.914

2.  Sequences of a hairpin structure in the 3'-untranslated region mediate regulation of human pulmonary surfactant protein B mRNA stability.

Authors:  Helen W Huang; David E Payne; Weizhen Bi; Su Pan; Shirley R Bruce; Joseph L Alcorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-24       Impact factor: 5.464

3.  A primate-specific RNA-binding protein (RBMXL3) is involved in glucocorticoid regulation of human pulmonary surfactant protein B (SP-B) mRNA stability.

Authors:  Lidan Liu; Xiangli Liu; Weizhen Bi; Joseph L Alcorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-03-10       Impact factor: 5.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.